MiNA Therapeutics Enters Research Collaboration with Nippon …
WEBApr 5, 2024 · –Collaboration includes licensing agreement option based on early-stage preclinical outcomes. LONDON, UK I April 04, 2024 I MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven ...
Harpoon Therapeutics Reports Clinical Progress Across All Four …
WEBDec 8, 2020 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Vaxcyte Announces FDA Clearance of Investigational New
WEBOct 20, 2023 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBUCB announces U.S. FDA approvals for BIMZELX [®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis. More news. Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.
Ranok Therapeutics Expands Clinical Testing of CHAMP® BRD4 …
WEBMar 11, 2024 · — Study follows ongoing Phase 1 trial in U.S. and will enroll patients in China to evaluate the first protein degrader developed using Ranok’s innovative CHAMP ® technology. BOSTON, MA, USA & HANGZHOU, China I March 11, 2024 I Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers ...
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive …
WEBJul 30, 2024 · Relfydess TM (RelabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL TM Technology, developed and manufactured by Galderma 1,2; This positive decision is based on results from the phase III READY clinical trial program, which showed that Relfydess TM delivered sustained results for six months, combined with an onset of action as early as day one, for ...
Sanofi announces end of program evaluating tusamitamab …
WEBDec 21, 2023 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Amberstone Biosciences Secures $12 Million Series A Financing to ...
WEBJan 3, 2022 · LAGUNA HILLS, CA, USA I January 03, 2021 I Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round.The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital ...
Sosei Heptares to Regain Full Ownership of GSK4381406
WEBNov 24, 2023 · GPR35 is a novel target with an established genetic association to IBD; UK regulatory approval received to commence first-in-human studies; Independent commercial analysis supports a worldwide peak sales opportunity of more than US$3 billion for GSK4381406 with its unique target product profile
Orbsen Therapeutics announces encouraging interim results from …
WEBGALWAY, Ireland I January 26, 2023 I Orbsen Therapeutics Limited (“Orbsen”), a global leader in stromal cell immunotherapies, today announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease (NEPHSTROM). NEPHSTROM is a randomized, double-blind, placebo-controlled Phase 1/2a, trial evaluating the safety, tolerability ...